FDA Sets Review Date for Tagrisso for Specific Lung Cancer Mutations
The FDA has granted priority review for AstraZeneca’s supplemental new drug application for Tagrisso (osimertinib) to treat adult patients with...
Mutations
The FDA has granted priority review for AstraZeneca’s supplemental new drug application for Tagrisso (osimertinib) to treat adult patients with...
